Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Active, not recruiting No phase listed Observational

Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP)

NCT03927768
View directory record Official record
Conditions
Breast Cancer
Interventions
Predictive Model, Breast Imagers
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

NEUROBALANCE Training to Improve Postural Control in Individuals With Traumatic Brain Injury

NCT06584591
View directory record Official record
Conditions
Traumatic Brain Injury, TBI, Diffuse Axonal Brain Injury, Brain Injuries, Traumatic
Interventions
Combined (Robotic balance training and high-definition transcranial direct current stimulation), Standard of Care Balance Training
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

H3N2 M2SR in Pediatric Population

NCT03553940
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine, Placebo, Quadrivalent MDCK Inactivated Influenza Vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 23, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional Results available

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD

NCT00499590
View directory record Official record
Conditions
Macular Degeneration
Interventions
bevasiranib, ranibizumab
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 23, 2026, 4:08 AM EDT
Terminated Phase 3 Interventional Results available

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

NCT02853604
View directory record Official record
Conditions
High Risk Cervical Cancer, Advanced Cervical Cancer
Interventions
ADXS11-001, Placebo
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
41
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes

NCT00004143
View directory record Official record
Conditions
Sickle Cell Anemia, Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pure Red Cell Aplasia
Interventions
Campath, Chemo and/or TBI Allo SCT
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
2
States / cities
Orlando, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Comparing Treatments for Multiple Myeloma

NCT00001750
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Stemgen
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 4:08 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

NCT04046445
View directory record Official record
Conditions
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
Interventions
ATP128, BI 754091, VSV-GP128
Drug
Lead sponsor
Amal Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Color Priming and Patient Decision-Making in the Emergency Department: Priming "Threat" in Patients With Low-Risk Chest Pain

NCT04749147
View directory record Official record
Conditions
Chest Pain, Cardiac Event
Interventions
Black and White Printed Survey, Red Printed Survey
Other
Lead sponsor
CHRISTUS Health
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

NCT01657461
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
Drug · Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 23, 2026, 4:08 AM EDT
Terminated Not applicable Interventional Results available

Pain Reduction Through Empowered Recovery (PRIME) Study

NCT05619510
View directory record Official record
Conditions
Pain, Chronic, Depressive Symptoms, Depression, Disability Physical
Interventions
PRIME Intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

UB-312 in Patients With Synucleinopathies

NCT05634876
View directory record Official record
Conditions
Multiple System Atrophy, Parkinson Disease
Interventions
UB-312 Injection, Placebo Injection
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

NCT02251288
View directory record Official record
Conditions
Avian Influenza, Immunisation
Interventions
Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013, MF59 adjuvant
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 47 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 23, 2026, 4:08 AM EDT
Not listed Phase 1 Interventional

Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer

NCT00016042
View directory record Official record
Conditions
Colorectal Cancer, Kidney Cancer
Interventions
lymphokine-activated killer cells, recombinant interferon alfa, sargramostim, fluorouracil
Biological · Drug
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm

NCT06728059
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET+ BPS_RL→AIDANET
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 23, 2026, 4:08 AM EDT
Terminated Phase 1 Interventional

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

NCT03878524
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Abemaciclib, Abiraterone, Afatinib, Bevacizumab, Bicalutamide, Biospecimen Collection, Bortezomib, Cabazitaxel, Cabozantinib, Capecitabine, Carboplatin, Celecoxib, Cobimetinib, Copanlisib, Dabrafenib, Dacomitinib, Darolutamide, Dasatinib, Doxorubicin, Durvalumab, Enasidenib, Entrectinib, Enzalutamide, Erlotinib, Everolimus, Fluorouracil, Idelalisib, Imatinib, Ipilimumab, Lenvatinib, Leucovorin, Lorlatinib, Losartan, Nab-paclitaxel, Neratinib, Nivolumab, Olaparib, Oxaliplatin, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Ponatinib, Quality-of-Life Assessment, Regorafenib, Ruxolitinib, Sirolimus, Sorafenib, Sunitinib, Trametinib, Trastuzumab Emtansine, Tretinoin, Vemurafenib, Venetoclax, Vismodegib, Vorinostat
Drug · Biological · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 23, 2026, 4:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infant Immunity Comparison of Breastfed and Bottlefed Infants

NCT02568579
View directory record Official record
Conditions
Infant Immunity Response and Immunoglobulin Diversity
Interventions
blood sample/ stool sample
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

PRIME Care (PRecision Medicine In MEntal Health Care)

NCT03170362
View directory record Official record
Conditions
Major Depression
Interventions
Pharmacogenetic Test
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
1,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
24
States / cities
North Little Rock, Arkansas • Palo Alto, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

NCT02935686
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function

NCT01182805
View directory record Official record
Conditions
Heart Failure, Diastolic
Interventions
Echocardiography system Ultra DCI Model 5000, Echocardiography machine GE Vivid E9, Diastolic function assessment
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 23, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 23, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 23, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Renal Metabolism of Glycolate to Oxalate

NCT04437225
View directory record Official record
Conditions
Healthy
Interventions
Low oxalate controlled Diet, Primed, continuous intravenous infusion of 13C2-Glycolate, Bolus intravenous infusion of 13C2-Glycolate, Oral bolus administration of 13C2-Glycolate
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 4:08 AM EDT